HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Sunho Biologics (PHIP Updates) - Some Points Worth the Attention

Akeso Biopharma Placement (9926.HK) - Would Investors Be Willing to Take a Gamble?

2024 High Conviction Update: Innovent (1801.HK) - Recent Promising Business Updates and 2024 Outlook

Important New Policy for China’s Innovative Drugs – The Game Rule Is About to Change Radically

Escalation of Israel-Hamas War - Here's How Investors Should Position Themselves in Dramatic Changes

WuXi AppTec (2359.HK/603259.CH) 2023 Results - Time to Prepare for the Worst

Equity Bottom-Up

Innovent Biologics Inc / Equity Bottom-Up

<ul>
<li>23H2 net loss significantly widened as cost control was not as tight as in 23H1. Expenses would remain high in 2024, since Innovent would continue expanding team in CVM field.</li>
<li>Innovent may think that not many players will join the competition of weight loss drug in short-term, but the actual commercialization of mazdutide after launch could be full of uncertainties.</li>
<li>It’s already good for Innovent to be breakeven in 2025. If Innovent breaks even in 2024, it will exceed expectations.Considering major policy shift, Innovent could experience a leap in valuation.</li>
</ul>


23H2 net loss significantly widened as cost control was not as tight as in 23H1. Expenses would remain high in 2024, since Innovent would continue expanding team in CVM field.
Innovent may think that not many players will join the competition of weight loss drug in short-term, but the actual commercialization of mazdutide after launch could be full of uncertainties.
It’s already good for Innovent to be breakeven in 2025. If Innovent breaks even in 2024, it will exceed expectations.Considering major policy shift, Innovent could experience a leap in valuation.


2024 High Conviction Update: Innovent (1801.HK) - Breakeven Is Still on Track Despite Soaring Costs